156 related articles for article (PubMed ID: 35342457)
1. Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies.
Savarirayan R; De Bergua JM; Arundel P; McDevitt H; Cormier-Daire V; Saraff V; Skae M; Delgado B; Leiva-Gea A; Santos-Simarro F; Salles JP; Nicolino M; Rossi M; Kannu P; Bober MB; Phillips J; Saal H; Harmatz P; Burren C; Gotway G; Cho T; Muslimova E; Weng R; Rogoff D; Hoover-Fong J; Irving M
Ther Adv Musculoskelet Dis; 2022; 14():1759720X221084848. PubMed ID: 35342457
[TBL] [Abstract][Full Text] [Related]
2. Low-Dose Infigratinib Increases Bone Growth And Corrects Growth Plate Abnormalities In An Achondroplasia Mouse Model.
Demuynck B; Flipo J; Kaci N; Dambkowski C; Paull M; Muslimova E; Shah BP; Legeai-Mallet L
J Bone Miner Res; 2024 Apr; ():. PubMed ID: 38590263
[TBL] [Abstract][Full Text] [Related]
3. Infigratinib, a selective FGFR1-3 tyrosine kinase inhibitor, alters dentoalveolar development at high doses.
Michel ZD; Aitken SF; Glover OD; Alejandro LO; Randazzo D; Dambkowski C; Martin D; Collins MT; Somerman MJ; Chu EY
Dev Dyn; 2023 Dec; 252(12):1428-1448. PubMed ID: 37435833
[TBL] [Abstract][Full Text] [Related]
4. Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma.
Lyou Y; Grivas P; Rosenberg JE; Hoffman-Censits J; Quinn DI; P Petrylak D; Galsky M; Vaishampayan U; De Giorgi U; Gupta S; Burris H; Rearden J; Li A; Wang H; Reyes M; Moran S; Daneshmand S; Bajorin D; Pal SK
Eur Urol; 2020 Dec; 78(6):916-924. PubMed ID: 32847703
[TBL] [Abstract][Full Text] [Related]
5. C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia.
Savarirayan R; Irving M; Bacino CA; Bostwick B; Charrow J; Cormier-Daire V; Le Quan Sang KH; Dickson P; Harmatz P; Phillips J; Owen N; Cherukuri A; Jayaram K; Jeha GS; Larimore K; Chan ML; Huntsman Labed A; Day J; Hoover-Fong J
N Engl J Med; 2019 Jul; 381(1):25-35. PubMed ID: 31269546
[TBL] [Abstract][Full Text] [Related]
6. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
[TBL] [Abstract][Full Text] [Related]
7. A registry of achondroplasia: a 6-year experience from the Czechia and Slovak Republic.
Pesl M; Verescakova H; Skutkova L; Strenkova J; Krejci P
Orphanet J Rare Dis; 2022 Jun; 17(1):229. PubMed ID: 35710503
[TBL] [Abstract][Full Text] [Related]
8. Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations.
Hyman DM; Tran B; Paz-Ares L; Machiels JP; Schellens JH; Bedard PL; Campone M; Cassier PA; Sarantopoulos J; Vaishampayan U; Chugh R; Mahipal A; Lockhart AC; Sessa C; Zander T; Ng M; Curigliano G; Bendiske J; Chen X; Choudhury S; Graus-Porta D; Lewis N; Perez Garcia JM; de Miguel-Luken MJ
JCO Precis Oncol; 2019 Dec; 3():1-13. PubMed ID: 35100734
[TBL] [Abstract][Full Text] [Related]
9. Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study.
Savarirayan R; Tofts L; Irving M; Wilcox WR; Bacino CA; Hoover-Fong J; Font RU; Harmatz P; Rutsch F; Bober MB; Polgreen LE; Ginebreda I; Mohnike K; Charrow J; Hoernschemeyer D; Ozono K; Alanay Y; Arundel P; Kotani Y; Yasui N; White KK; Saal HM; Leiva-Gea A; Luna-González F; Mochizuki H; Basel D; Porco DM; Jayaram K; Fisheleva E; Huntsman-Labed A; Day JRS
Genet Med; 2021 Dec; 23(12):2443-2447. PubMed ID: 34341520
[TBL] [Abstract][Full Text] [Related]
10. Emerging therapies for Achondroplasia: changing the rules of the game.
Kumble S; Savarirayan R
Expert Opin Emerg Drugs; 2021 Dec; 26(4):425-431. PubMed ID: 34758681
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and Exposure-Response of Vosoritide in Children with Achondroplasia.
Chan ML; Qi Y; Larimore K; Cherukuri A; Seid L; Jayaram K; Jeha G; Fisheleva E; Day J; Huntsman-Labed A; Savarirayan R; Irving M; Bacino CA; Hoover-Fong J; Ozono K; Mohnike K; Wilcox WR; Horton WA; Henshaw J
Clin Pharmacokinet; 2022 Feb; 61(2):263-280. PubMed ID: 34431071
[TBL] [Abstract][Full Text] [Related]
12. Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib.
Yu J; Mahipal A; Kim R
Onco Targets Ther; 2021; 14():5145-5160. PubMed ID: 34720591
[TBL] [Abstract][Full Text] [Related]
13. Vosoritide treatment for children with hypochondroplasia: a phase 2 trial.
Dauber A; Zhang A; Kanakatti Shankar R; Boucher K; McCarthy T; Shafaei N; Seaforth R; Castro MG; Dham N; Merchant N
EClinicalMedicine; 2024 May; 71():102591. PubMed ID: 38813446
[TBL] [Abstract][Full Text] [Related]
14. Achondroplasia: from genotype to phenotype.
Richette P; Bardin T; Stheneur C
Joint Bone Spine; 2008 Mar; 75(2):125-30. PubMed ID: 17950653
[TBL] [Abstract][Full Text] [Related]
15. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial.
Savarirayan R; Tofts L; Irving M; Wilcox W; Bacino CA; Hoover-Fong J; Ullot Font R; Harmatz P; Rutsch F; Bober MB; Polgreen LE; Ginebreda I; Mohnike K; Charrow J; Hoernschemeyer D; Ozono K; Alanay Y; Arundel P; Kagami S; Yasui N; White KK; Saal HM; Leiva-Gea A; Luna-González F; Mochizuki H; Basel D; Porco DM; Jayaram K; Fisheleva E; Huntsman-Labed A; Day J
Lancet; 2020 Sep; 396(10252):684-692. PubMed ID: 32891212
[TBL] [Abstract][Full Text] [Related]
16. C-type natriuretic peptide plasma levels are elevated in subjects with achondroplasia, hypochondroplasia, and thanatophoric dysplasia.
Olney RC; Prickett TC; Espiner EA; Mackenzie WG; Duker AL; Ditro C; Zabel B; Hasegawa T; Kitoh H; Aylsworth AS; Bober MB
J Clin Endocrinol Metab; 2015 Feb; 100(2):E355-9. PubMed ID: 25387261
[TBL] [Abstract][Full Text] [Related]
17. Severe achondroplasia due to two de novo variants in the transmembrane domain of FGFR3 on the same allele: A case report.
Nagata T; Matsushita M; Mishima K; Kamiya Y; Kato K; Toyama M; Ogi T; Ishiguro N; Kitoh H
Mol Genet Genomic Med; 2020 Mar; 8(3):e1148. PubMed ID: 31975530
[TBL] [Abstract][Full Text] [Related]
18. Lifetime impact of achondroplasia study in Europe (LIAISE): findings from a multinational observational study.
Maghnie M; Semler O; Guillen-Navarro E; Selicorni A; Heath KE; Haeusler G; Hagenäs L; Merker A; Leiva-Gea A; González VL; Raimann A; Rehberg M; Santos-Simarro F; Ertl DA; Gregersen PA; Onesimo R; Landfeldt E; Jarrett J; Quinn J; Rowell R; Pimenta J; Cohen S; Butt T; Shediac R; Mukherjee S; Mohnike K
Orphanet J Rare Dis; 2023 Mar; 18(1):56. PubMed ID: 36922864
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and safety after once and twice a day doses of meclizine hydrochloride administered to children with achondroplasia.
Kitoh H; Matsushita M; Mishima K; Nagata T; Kamiya Y; Ueda K; Kuwatsuka Y; Morikawa H; Nakai Y; Ishiguro N
PLoS One; 2020; 15(4):e0229639. PubMed ID: 32282831
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor receptor-3 as a therapeutic target for Achondroplasia--genetic short limbed dwarfism.
Aviezer D; Golembo M; Yayon A
Curr Drug Targets; 2003 Jul; 4(5):353-65. PubMed ID: 12816345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
